A01  Novel childhood genitourinary manifestations of DICER1 syndrome. Maria Apellaniz-Ruiz, Lady Davis Institute, McGill University, Montreal, Quebec, Canada.

A02  Pediatric ovarian cancer in the United States: incidence trends over four decades. Kara Christopher, Saint Louis University Cancer Center, Saint Louis, Missouri.

A03  Prevalence and spectrum of germline mutations in children with high-risk cancer. Noemi Fuentes-Bolanos, Kid’s Cancer Center, Sydney, NSW, Australia.

A04  Childhood cancer incidence among specific Asian and Pacific Islander populations in the U.S. Kristin Moore, University of Minnesota, Minneapolis, MN.

A05  Incidence and trends in head and neck cancer among United States’ pediatric, adolescent and young adult population. Nosayaba Osazuwa-Peters, Saint Louis University School of Medicine, St. Louis, MO.

A06  The added value of examining germline variants in a precision cancer therapy study. Jaclyn Schienda, Dana-Farber Cancer Institute, Boston, MA.

A07, PR05  T cell receptor (TCR) based immunotherapy in pediatric malignancy: Addressing the challenge of early metastasis and low immunogenicity. Stefan Burdach, Department of Pediatrics and Children's Cancer Research Center, Technical University of Munich School of Medicine and CCC München - Comprehensive Cancer Center, DKTK German Cancer Consortium, Munich, Bavaria, Germany.

A08  Development of FGFR4 specific Chimeric Antibody Receptor (CAR) T cell and Bispecific T Cell Engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy. Adam (Tai Chi) Cheuk, National Cancer Institute, Bethesda, MD.

A09  Glypican-2 targeted CAR T-cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity. Sabine Heitzeneder, Stanford Cancer Institute, Stanford, California.
A10 Constitutive HIF activity enhances T cell anti-tumor immunity and memory T cell formation in the murine adoptive cell therapy model. Colette Lauhan, University of California San Diego, San Diego, CA.

A11 A comprehensive and integrative omic analysis of multiply relapsed refractory pediatric pre-B cell acute lymphoblastic leukemia predicts response to CD19 CAR T cell therapy. Katherine Masih, National Institutes of Health, Bethesda, MD.

A12, PR04 Locoregionally Administered B7H3-targeting CAR T cells Mediate Potent Antitumor Effects in Atypical Teratoid/Rhabdoid Tumor. Johanna Theruvath, Stanford University, Palo Alto, California.

A13 Immunogenomic approaches to optimize immunotherapeutic targeting of neuroblastoma. Meijie Tian, National Cancer Institute, Bethesda, Maryland.

A14 Exploiting DNA damage repair defects to enhance PD-L1 expression in Ewing sarcoma. Kelly Bailey, University of Pittsburgh School of Medicine, Pittsburgh, PA.

A15 Improving immune recognition of shared tumor associated antigens in pediatric tumors using a multi-modal oncolytic virus. Kevin Cassady, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio.

A16 Genomic and immunologic characterization of a cohort of INI1-deficient pediatric cancers. Suzanne Forrest, Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, Boston, MA.

A17 HHLA2 IS A NEW IMMUNE CHECKPOINT EXPRESSED IN PEDIATRIC HODGKIN LYMPHOMA. Scott Moerdler, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

A18 Characterization of checkpoint inhibitors in the tumor microenvironment (TME) and peripheral blood in endemic Burkitt Lymphoma. Priya Saikumar lakshmi, University of Massachusetts Medical School, Worcester, MA.

A19 Immunological dysfunctions of NSG mice confer higher engraftment levels of xenograft Ewing sarcoma metastasis in the PuMA model compared to NOD-SCID mice. Renata Scopim-Ribeiro, University of British Columbia, Vancouver, BC, Canada.

A20 Single cell immune TCR repertoire profiling in the context of immunotherapy by using three 10x Genomics libraries. Xiaoping Su, MD Anderson Cancer Center, Houston, TX.

A21 Time-to-event Bayesian optimal interval design to accelerate phase I pediatric oncology trials. Ying Yuan, MD Anderson Cancer Center, Houston, TX.
A22  YAP1 knockout in vitro models of medulloblastoma showed improved response to Sonidegib. Gustavo Alencastro Veiga Cruzeiro, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

A23  Novel approaches to Ewing sarcoma therapy. Dauren Alimbetov, UT Health at San Antonio, Department of Molecular Medicine, Greehey Children’s Cancer Research Institute, San Antonio, TX.

A24  Identifying BRCAAness in osteosarcoma with DNA-methylation profiling and gene expression signatures. Maxim Barenboim, Department of Pediatrics and Children’s Cancer Research Center, Kinderklinik München Schwabing, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.


A28  Targeted sequencing in 388 patients with high-risk or recurrent / refractory pediatric extracranial solid malignancies: An interim report from the GAIN Consortium / iCat2 Study. Laura Corson, Dana-Farber Cancer Institute, Boston, MA.

A29  Respective role of TEAD and Smad signaling in YAP-mediated osteosarcoma tumor growth and lung metastatic development. Geoffroy Danieau, Nantes University, Nantes, France.

A30  Alisertib acts synergistically with sonidegib by modulating primary cilia assembly in a pediatric RELA ependymoma cell line. Taciani de Almeida Magalhães, University of São Paulo, Ribeirão Preto, SP, Brazil.

A31  Podxl as therapeutic target for metastasis. Anne-Chloe Dhez, British Columbia Cancer Research Centre, Vancouver, BC, Canada.

A32  Selective inhibition of AuroraA by LY3295668 erbumine in neuroblastoma models induces apoptosis through a combination of S-phase DNA damage and mitotic arrest. Michele Dowless, Eli Lilly, Indianapolis, IN.

A33  HIF2 in pediatric high grade glioma and its targeting. Natacha ENTZ-WERLE, CHU Strasbourg Hautepierre, Strasbourg, Bas-Rhin, France.
A34  Hypoxia signaling pathway is frequently involved in pediatric osteosarcoma microenvironment, as diagnostic and prognostic biomarkers, but also as new therapeutic targets. Natacha Entz-WErlé, UMR CNRS 7021, Strasbourg, Bas-Rhin, France.

A35  P-glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma. Jamie Fletcher, Children’s Cancer Institute Australia, UNSW Sydney, NSW, Australia.


A38  Validation of potential therapies for treatment of fatal pediatric brain tumors DIPG and AT/RT using a novel rapid intracranial model in zebrafish. Harpreet Kaur, Johns Hopkins University, Baltimore, Maryland.

A39  Molecular characterization of ETMRs reveals role for R-loop mediated genomic instability and new treatment options. Marcel Kool, Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany.

A40  Integration of high throughput drug screening on patient derived organoids into paediatric precision medicine programs: the future is now!. Karin Langenberg, Princess Maxima Center, Utrecht, the Netherlands.

A41  Novel mithramycin analogues with improved pharmacological profile and efficacy in ETS transcription factor driven tumors. Markos Leggas, University of Kentucky, Lexington, KY.

A42  EphB2 a potential therapeutic target for paediatric medulloblastoma. Yuchen Li, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

A43  Effects of transcriptional dysregulation on the DNA damage response in Ewing’s Sarcoma. Matthew Rollins, University of Arizona, Tucson, AZ.

A44  Comparative gene expression analysis for identification and prioritization of therapeutic targets in a cohort of childhood cancers. Lauren Sanders, Department of Biomolecular Engineering, UC Santa Cruz Genomics Institute, Santa Cruz, CA.

A45  Targeted drug therapies for osteosarcoma. Leanne Sayles, University of California San Francisco, San Francisco, California.
A46  Charting the synthetic lethality landscape in pediatric cancer to advance whole-exome precision-based treatments. Fiorella Schischlik, National Cancer Institute, Bethesda, Maryland.

A47 BMI1 constitutes a novel therapeutic vulnerability in fusion-positive rhabdomyosarcoma. Robert Schnepp, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Division of Pediatric Hematology, Oncology, and Bone Marrow Transplant, Emory University School of Medicine, Atlanta, GA.

A48 YB-1-based Oncolytic Virotherapy In Combination With CDK4/6-inhibitors Against Ewing Sarcoma. Sebastian Schober, Technical University of Munich, Munich, Bavaria, Germany.


A50 Targeted Therapies for Children and Young Adults with Cancer: Single-Patient Use (SPU) Experience at Three Large Pediatric Cancer Programs. Neerav Shukla, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

A51 Advances in the etiology and therapeutics of a lethal childhood cancer, Fibrolamellar Hepatocellular Carcinoma. Sanford Simon, Rockefeller University, New York, NY.


A53 Synergistic interaction of HDACi and PLK1i in Group 3 MYC-amplified medulloblastoma. Gintvile Valinciute, Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

A54 Parallel Targeting of RAF/MEK/ERK Pathway in RAS-mutant Embryonal Rhabdomyosarcoma. Angelina Vaseva, Greehey Children’s Cancer Research Institute, UT Health SA, San Antonio, TX.

A55 Defining the transcriptional regulation of Pediatric AML as a new strategy to find potential druggable vulnerabilities. Joanna Yi, Baylor College of Medicine, Houston, TX.

A56 Effect of chemotherapy on gut microbiota and microbiota-derived metabolites in children with cancer. Abderrahim Benmoussa, Research Center of Sainte-Justine UHC, Université de Montréal, Montréal, Québec, Canada.

A57 Feasibility of Physical Activity in Children with Cancer: A Multidisciplinary Program in the context of the VIE study. Maxime Caru, Canada, Sainte-Justine University Hospital Research Centre, Canada.
A58  Curation of Pediatric Cancer Variants within the Clinical Genome Resource (ClinGen). Alanna Church, Boston Children's Hospital, Boston, MA.

A59  Sequencing identifies diagnostically relevant alterations in pediatric solid tumor patients. Alanna Church, Boston Children's Hospital, Boston, MA.

A60  Transcriptional profile of CD56negCD16pos Natural Killer cells within endemic Burkitt lymphoma. Catherine Forconi, University of Massachusetts Medical School, Worcester, MA.

A61, PR10  Disruption of IL6-mediated paracrine signaling to prevent pulmonary metastasis. John Hinckley, The Ohio State University, Nationwide Children's Hospital, Columbus, Ohio.


A64  Functional genomics of metastatic ewing sarcoma. Wajih Jawhar, McGill University, Montreal, Quebec, Canada.

A65  Alveolar soft part sarcoma in children and adolescents: A single institute retrospective analysis. Sena Kang, Seoul National University College of Medicine, Seoul, Republic of Korea.

A66, PR03  Sex ratio disparities and the risk of childhood cancer: evaluating the mediating effect of birth defects among 15,000 childhood cancer cases. Erin Marcotte, University of Minnesota, Minneapolis, MN.

A67  Improving Tissue Allocation for Research in Pediatric Solid Tumors. R. Seth Pinches, Boston Children's Hospital, Boston, MA.

A68  Optical Coherence Tomography improves sub-clinical Retinoblastoma Management. Sameh Soliman, the Hospital for Sick Children, Toronto, ON, Canada.

A69, PR17  Immunogenomic landscape of pediatric solid malignancies. Jun Wei, National Cancer Institute, Bethesda, MD.

A70  Aqueous humor is superior to blood as a liquid biopsy for Retinoblastoma. Liya Xu, Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA.
GD2 is a Macrophage Checkpoint Molecule and Combined GD2/CD47 Blockade Results in Synergistic Effects and Tumor Clearance in Xenograft Models of Neuroblastoma and Osteosarcoma. Robbie Majzner, Stanford University School of Medicine, Stanford, CA.

The immunogenomic landscape of pediatric primary solid tumors. Arash Nabbi, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Mithramycin evicts SWI/SNF from chromatin to induce epigenetic reprogramming in rhabdoid tumor. Maggie Chasse, Van Andel Research Institute, Grand Rapids, MI.

Generation of the first genetically defined tumorigenic model of Ewing Sarcoma expressing EWS-FLI1. Nilay Shah, Nationwide Children’s Hospital, Columbus, OH.
Poster Session B
Thursday, September 19, 2019
12:50-3:15 p.m.

B01  Alternative splicing as a therapeutic vulnerability in pediatric rhabdomyosarcoma. Dawn Chandler, Nationwide Children's Hospital, Columbus, OH.

B02  5-hydroxymethylcytosine profiles in circulating cell-free DNA are biomarkers of disease burden in children with neuroblastoma. Mark Applebaum, University of Chicago, Chicago, IL.

B03  Methods for integrated analysis of RNA and DNA sequencing in pediatric cancers. Marcus Breese, University of California San Francisco, San Francisco, California.

B04  Three distinct subgroups of Wilms tumors with novel molecular features and important clinical implications are defined by genome-wide DNA methylation profiles. Jack Brzezinski, Hospital for Sick Children, Toronto, Ontario, Canada.

B05, PR01  Three-hit model of Wilms tumor formation reveals immunogenic transcriptional subtypes. Kenneth Chen, UT Southwestern, Dallas, TX.

B06  Candidate differentiation stall in epithelial mesenchymal transition in H3K27M diffuse midline glioma. Allison Cheney, Department of Molecular, Cell and Developmental Biology, UC Santa Cruz Genomics Institute, Santa Cruz, CA.

B07  Prospective germline next-generation sequencing in pediatric patients with neuroblastoma identifies frequent alterations in genes involved in DNA damage repair. Sarah Cohen-Gogo, The Hospital for Sick Children, Toronto, ON, Canada.

B08  Beyond synthetic lethality: Multiple mechanisms can explain genetic interactions within childhood cancer. Josephine Daub, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

B09  Epigenetic changes mediated by H3.3 G34R mutation in a CRISPR-edited pediatric glioblastoma cell line. Shriya Deshmukh, McGill University, Montreal, QC, Canada.
B10  Rhabdomyosarcoma requires MYC family genomic events to pathogenically subvert core-regulatory circuitry. Adam Durbin, Dana-Farber Cancer Institute, Boston, MA.

B11, PR11  EP300 controls the oncogenic enhancer landscape of high-risk neuroblastoma. Adam Durbin, Dana-Farber Cancer Institute, Boston, MA.

B12  PAX3 translocations co-opt super enhancers and intrinsically disordered fusion partners in rhabdomyosarcoma. David Milewski, Genetics Branch, NCI, NIH, Bethesda, MD.

B13  Leveraging cloud based computational resources for gene fusion discovery with potential clinical implications for pediatric solid tumor patients. Alma Imamovic, Dana-Farber Cancer Institute & Broad Institute, Boston, Massachusetts.

B14  Pinpointing the origins of pediatric brain tumors using single cell transcriptomic analysis. Selin Jessa, Lady Davis Institute for Medical Research, Montreal, QC, Canada.

B15  Genomic Classification and Prognosis in Rhabdomyosarcoma: A report from the Children’s Oncology Group, the Institute of Cancer Research and the National Cancer Institute. Javed Khan, NCI, Bethesda, MD.

B16  MECOM dysregulation is associated with poor outcome in pediatric therapy-related myeloid neoplasms. Tamara Lamprecht, St. Jude Children’s Research Hospital, Memphis, TN.


B19  Identification of physiologically relevant EWS-FLI1 target genes in Ewing’s sarcoma via CRISPRa screening. Vadim Saratov, Children’s University Hospital Zurich, Zurich, Switzerland.


B21  Childhood Cancer Molecular Map (C2M2) to define medulloblastoma heterogeneity and predict treatment response. Huwate Yeerna, Stanford University School of Medicine, Stanford, CA.
B22  Cell state and lineage specification are controlled by epigenetic landscapes regulating the core transcriptional regulatory circuitry in pediatric neuroblastoma. Mark Zimmerman, Dana-Farber Cancer Institute, Boston, MA.

B23  EWS-FLI1 partners with EWSR1 to regulate transcription in Ewing sarcoma. Nasiha Ahmed, The University of Arizona, Tucson, AZ.

B24  EWSR1-FLI1 expression heterogeneity and the impact on BRCA1 dependent metabolism and metastasis. Alexander Bishop, GCCRI, UT-H SA, San Antonio, Texas.

B25  HNRNPH1-dependent splicing of the fusion oncogene EWS-FLI1 reveals a targetable RNA G-quadruplex interaction. Natasha Caplen, Genetics Branch, CCR, NCI, Bethesda, MD.

B26  Pro-metastatic effect of ICG-001, a β-catenin/CBP dependent transcription inhibitor, in osteosarcoma. Geoffroy Danieau, Nantes University, Nantes, France.


B28  A cross-species enhancer activity analysis approach to identify the Ewing sarcoma cell-of-origin. Martin Distel, CCRI, Vienna, Vienna, Austria.

B29  Validation of a model of pediatric leukemia based on pluripotent stem cells using mass cytometry. Joan Domingo Reines, Gene Regulation, Stem Cells and Development Group, GENYO - Centre for Genomics and Oncological Research - Pfizer/University of Granada/Junta de Andalucía, Granada, Spain.

B30  ARID1A is a haploinsufficient tumor suppressor for N-Myc transformation of neural crest cells. Kevin Freeman, University of Tennessee Health Science Center, Memphis, Tennessee.

B31, PR12  IL6 Mediated Self-Seeding Functions to Prevent Osteosarcoma Metastasis. Amy Gross, Nationwide Children’s Hospital, Columbus, Ohio.

B32  ASAP1 regulates differentiation in myoblasts and PAX-FOXO1 fusion-negative rhabdomyosarcoma. Katie Hebron, National Cancer Institute, National Institutes of Health, Bethesda, MD.

B33, PR08  Lactate dehydrogenase A is a pharmacologically tractable EWS-FLI1 transcriptional target that regulates the glycolytic dependence of Ewing sarcoma. Christine Heske, National Cancer Institute, Bethesda, MD.
B34  Cord blood CD34+ HSPCs: An in vitromodel system for characterizing NUP98 fusions. Ryan Hiltenbrand, St. Jude Children’s Research Hospital, Memphis, TN.

B35  Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion-Negative Rhabdomyosarcoma. Myron Ignatius, Greehey Children's Cancer Research Institute, Department of Molecular Medicine, UT Health Sciences Center, San Antonio, TX.

B36  A Novel Model of Osteosarcomagenesis Reveals Dysregulation of Oxidative Phosphorylation. Brittany Jewell, MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas.


B38  Surgical excision of the primary tumor in osteosarcoma model results in enhanced metastatic growth by modulating the lung immune microenvironment. Michelle Kallis, The Elmezzi Graduate School of Molecular Medicine, Northwell Health, Karches Center for Oncology, The Feinstein Institute for Medical Research and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Surgery, Donald and Barbara Z, Manhasset, NY.

B39  Modulation of insulin receptor alternative splicing to develop cancer therapeutics. Safiya Khurshid, Nationwide Children’s Hospital, Columbus, OH.

B40  EWS-FLI1 orchestrates Ewing sarcoma plasticity through a post-translational modification cascade regulating FOXM1 stability. Heinrich Kovar, St. Anna Children’s Cancer Research Institute, Vienna, Austria.

B41  Genomic landscape of somatic mutations in osteosarcomas. Ana Krepisch, Human Genome and Stem-Cell Research Center, Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, Brazil.

B42  Mutant RAS represses CASZ1, a novel regulator of MYOD and MYOG to inhibit embryonal rhabdomyosarcoma differentiation. Zhihui Liu, National Cancer Institute, Bethesda, Maryland.

B43  The c-Myc/AKT1/TBX3 axis is important to target in the treatment of embryonal rhabdomyosarcoma. Hapiloe Mabaruti Maranyane, University of Cape Town, Cape Town, Western Cape, South Africa.

B44  Role of EMT transcription factors in the metastatic potential of osteosarcoma. Sana Mohiuddin, MD Anderson Cancer Hospital, Houston, Texas.
B45  Therapeutic potential of splicing in RMS: SRSF2 binding modulation controls MDM2 alternative splicing. Matias Montes, Nationwide Children's Hospital, Columbus, OH.


B47  Overexpression of TLX3 or HOXA9 in association mutant IL7Rα are sufficient to generate T-ALL in vivo. Gisele Rodrigues, Cancer and Inflammation Program, National Cancer Institute, Frederick, Maryland.

B48  A LIN28B-PDZ Kinase Axis Promotes Neuroblastoma Metastasis. Robert Schnepp, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Division of Pediatric Hematology, Oncology, and Bone Marrow Transplant, Emory University School of Medicine, Atlanta, GA.

B49  Modeling a pathogenic SAMD9 mutation in human induced pluripotent stem cells. Jason Schwartz, St. Jude Children's Research Hospital, Memphis, TN.

B50  Targeting EWS/FLI fusion oncoprotein stability/degradation in Ewing sarcoma. Bo Kyung Alex Seong, Dana-Farber Cancer Institute, Boston, MA.

B51  Adaptation to oncogene-induced metabolic stress by MondoA (MLXIP) drives common Acute Lymphoblastic Leukemia (cALL) malignancy. Alexandra Sipol, Children’s Cancer Research Center, Department of Pediatrics, Technische Universität München, Munich, Germany.

B52  Ewing Sarcoma: A Case Study of Clonal Aneuploidy and DNA Damage Repair in Pediatric Cancer. Xiaofeng Su, Koch Institute, Massachusetts Institute of Technology, Cambridge, MA.

B53, PR09  STAG2 mutations alter topological organization of the genome and cis-mediated interactions. Didier Surdez, Institut Curie, Paris, France.


B55  MYCN promotes m6a dependent translation of eEF2K mRNA during adaptation to ER stress. Andrii Vislovukh, Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.

B56  A CRISPR/Cas9 domain screen identifies a small motif in the PAX3-FOXO1 transactivation domain relevant for tumor maintenance in alveolar rhabdomyosarcoma. Marco Wachtel, University Children’s Hospital Zurich, Zurich, Switzerland.
B57  A combination of IL7Rα and NRAS mutations sheds light on the oncogenesis of T-cell acute lymphoblastic leukemia in a murine model. Hila Winer, NIH/NCI, Frederick, MD.

B58, PR14  Ewing sarcoma cells exploit the IL1RAP-CTH axis to drive oxidative stress adaptation and lung metastasis. Haifeng Zhang, University of British Columbia, Vancouver, BC, Canada.

B59  Cardiometabolic complications after pediatric cancer: associations with chemotherapeutic agents and body-mass-index fluctuations. Veronique Belanger, Research Center of Sainte-Justine UHC and Université de Montréal, Montreal, Quebec, Canada.

B60  Exposure assessment among an adult population on radiation therapy, chemotherapy and other cancer therapies in childhood. Lara Kim Brackmann, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Bremen, Germany.

B61  Improvement of Physical Activity Training in Childhood Acute Lymphoblastic Leukemia Survivors: New Specific Equation to Predict the Peak Oxygen Uptake from the Six-Minute Walk Test. Maxime Caru, Université de Montréal, Montréal, Canada.

B62  The Need to Improve Exercise Prescriptions to Support Care in Pediatric Oncology. Maxime Caru, Université de Montréal, Montréal, Canada.

B63  Survivorship, vision and eye salvage following pars plana vitrectomy for residual active or recurrent retinoblastoma. Zhao Xun Feng, University of Ottawa, Ottawa, Ontario, Canada.

B64, PR15  Acting at a distance: Medulloblastoma secreted ligands disrupt normal neural stem cell function. Alexander Gont, Hospital for Sick Children, Toronto, Ontario, Canada.

B66  Nutritional intakes are associated with HDL-cholesterol levels in survivors of childhood acute lymphoblastic leukemia. Sophia Morel, Research Center of Sainte-Justine UHC and Université de Montréal, Montreal, Quebec, Canada.

B67  EGFR as a target in Pediatric Solid Tumors. Catherine Albert, Seattle Children's Research Institute, Seattle, WA.

B68  Spatial and temporal conditions for Smarcb1 deletion determines mouse AT/RT (Atypical teratoid/Rhabdoid tumor) subtype. Zhi-Yan Han, institut Curie, Paris, France.

B69  Epigenomics and Single-cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis. Caroline Hutter, St. Anna Children's Cancer Research Institute, Vienna, Austria, Austria.
B70  Clonal Evolution of chemotherapy resistant rhabdomyosarcoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. Michael Kinnaman, Memorial Sloan Kettering Cancer Center, New York, NY.

B71  Molecular heterogeneity and novel oncogenic fusions in RELA- and YAP1-negative supratentorial ependymoma. David Norali Ghasemi, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

B72  Dissecting the heterogeneity of metastatic neuroblastoma cells by single-cell RNA-seq. Alice Shan, University of Toronto, Toronto, Canada.

B73  Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Tanvi Sharma, Hopp Children’s Cancer Centre at National Centre for Tumour Diseases Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany.

B74  Investigating the role of tumor:bone microenvironment crosstalk in Ewing sarcoma progression. Kelsey Temprine, University of Michigan Medical School, Ann Arbor, MI.

B75, PR16  Comprehensive transcriptomic characterization of 1,400 sarcomas for diagnosis and immune contexture. Julien Vibert, Institut Curie, Paris, France.

B76  Characterizing vascular invasion in hepatoblastoma. Sarah Woodfield, Baylor College of Medicine, Houston, TX.

B78  Role of noradrenergic core regulatory circuitry transcription factors in neuroblastoma cell identity. Agathe Peltier, Institut Curie, SIREDO Oncology Center (Care, innovation and research for children and AYA with cancer), Inserm U830, PSL Research University, Equipe labellisée Ligue Nationale contre le cancer, Paris, France.